DE69521002D1 - Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens - Google Patents

Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens

Info

Publication number: DE69521002D1
Authority: DE; Germany
Prior art keywords: ovarian cancer; mutations; ovarian; breast; breast cancer
Prior art date: 1994-08-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69521002T

Other languages

English (en)

Other versions

DE69521002T3 (de

DE69521002T2 (de

Inventor

Donna M Shattuck-Eidens

Jacques Simard

Mitsuru Emi

Yusuke Nakamura

Francine Durocher

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Utah Research Foundation Inc

Original Assignee

CT DE RECH DU CHUL SAINTE FOY

Cancer Institute

Myriad Genetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-12

Filing date

1995-08-11

Publication date

2001-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27569596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69521002(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-07 Priority claimed from US08/483,553 external-priority patent/US5709999A/en

1995-06-07 Priority claimed from US08/480,784 external-priority patent/US5693473A/en

1995-08-11 Application filed by CT DE RECH DU CHUL SAINTE FOY, Cancer Institute, Myriad Genetics Inc filed Critical CT DE RECH DU CHUL SAINTE FOY

2001-06-28 Application granted granted Critical

2001-06-28 Publication of DE69521002D1 publication Critical patent/DE69521002D1/de

2001-11-15 Publication of DE69521002T2 publication Critical patent/DE69521002T2/de

2010-02-25 Publication of DE69521002T3 publication Critical patent/DE69521002T3/de

2015-08-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Marine Sciences & Fisheries (AREA)
Animal Behavior & Ethology (AREA)
Hospice & Palliative Care (AREA)
Public Health (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

DE69521002T 1994-08-12 1995-08-11 Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens Expired - Lifetime DE69521002T3 (de)

Applications Claiming Priority (14)

Application Number	Priority Date	Filing Date	Title
US28922194A	1994-08-12	1994-08-12
US289221		1994-08-12
US30026694A	1994-09-02	1994-09-02
US300266		1994-09-02
US30810494A	1994-09-16	1994-09-16
US308104		1994-09-16
US34882494A	1994-11-29	1994-11-29
US348824		1994-11-29
US40930595A	1995-03-24	1995-03-24
US409305		1995-03-24
US480784		1995-06-07
US08/483,553 US5709999A (en)	1994-08-12	1995-06-07	Linked breast and ovarian cancer susceptibility gene
US08/480,784 US5693473A (en)	1994-08-12	1995-06-07	Linked breast and ovarian cancer susceptibility gene
US483553		1995-06-07

Publications (3)

Publication Number	Publication Date
DE69521002D1 true DE69521002D1 (de)	2001-06-28
DE69521002T2 DE69521002T2 (de)	2001-11-15
DE69521002T3 DE69521002T3 (de)	2010-02-25

Family

ID=27569596

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69521002T Expired - Lifetime DE69521002T3 (de)	1994-08-12	1995-08-11	Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens

Country Status (16)

Country	Link
EP (1)	EP0705903B2 (de)
JP (1)	JP2002503943A (de)
CN (1)	CN1172502A (de)
AT (1)	ATE201445T1 (de)
AU (1)	AU686004B2 (de)
CA (1)	CA2196797C (de)
DE (1)	DE69521002T3 (de)
DK (1)	DK0705903T3 (de)
ES (1)	ES2158048T5 (de)
FI (1)	FI970513A (de)
GR (1)	GR3036322T3 (de)
MX (1)	MX9701075A (de)
NO (1)	NO970624L (de)
NZ (1)	NZ291621A (de)
PT (1)	PT705903E (de)
WO (1)	WO1996005306A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995019369A1 (en)	1994-01-14	1995-07-20	Vanderbilt University	Method for detection and treatment of breast cancer
AU707348B2 (en) *	1995-01-17	1999-07-08	Vanderbilt University	Method for detection and treatment of breast cancer
US5654155A (en) *	1996-02-12	1997-08-05	Oncormed, Inc.	Consensus sequence of the human BRCA1 gene
US6951721B2 (en)	1996-02-12	2005-10-04	Gene Logic Inc.	Method for determining the haplotype of a human BRCA1 gene
US6838256B2 (en) *	1996-02-12	2005-01-04	Gene Logic Inc.	Coding sequences of the human BRCA1 gene
US5891857A (en) *	1996-02-20	1999-04-06	Vanderbilt University	Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
AU4586697A (en) *	1996-09-20	1998-04-14	Board Of Regents, The University Of Texas System	Compositions and methods comprising bard1 and other brca1 binding proteins
US6623938B2 (en)	1997-01-21	2003-09-23	Human Genome Sciences, Inc.	I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
US5965377A (en) *	1997-03-24	1999-10-12	Baystate Medical Center	Method for determining the presence of mutated BRCA protein
AU754748B2 (en)	1997-06-04	2002-11-21	Rijksuniversiteit Te Leiden	A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
US6492109B1 (en)	1997-09-23	2002-12-10	Gene Logic, Inc.	Susceptibility mutation 6495delGC of BRCA2
CA2308766C (en)	1997-11-06	2007-03-20	Oklahoma Medical Research Foundation	Diagnostic assay for cancer susceptibility
US6177410B1 (en)	1997-12-05	2001-01-23	Vanderbilt University	Therapeutic methods for prostate cancer
US6686163B2 (en)	1998-05-06	2004-02-03	Gene Logic Inc.	Coding sequence haplotype of the human BRCA1 gene
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
DE60335359D1 (de)	2002-04-30	2011-01-27	Kudos Pharm Ltd	Phthalazinonderivate
PL224844B1 (pl)	2002-05-02	2017-02-28	Wyeth Holdings Llc	Zastosowanie kompozycji zawierającej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22
GB0210121D0 (en)	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
WO2005053662A1 (en)	2003-12-01	2005-06-16	Kudos Pharmaceuticals Limited	Dna damage repair inhibitors for treatment of cancer
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
KR101138862B1 (ko) *	2005-02-14	2012-05-14	삼성전자주식회사	단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법
KR101206028B1 (ko)	2005-03-05	2012-11-28	삼성전자주식회사	유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
CA2651995C (en)	2006-05-18	2017-04-25	Molecular Profiling Institute, Inc.	System and method for determining individualized medical intervention for a disease state
US8768629B2 (en)	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
JP5271897B2 (ja)	2006-05-31	2013-08-21	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ	ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体
UY30639A1 (es)	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
WO2008084261A1 (en)	2007-01-10	2008-07-17	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2009034326A1 (en)	2007-09-14	2009-03-19	Astrazeneca Ab	Phthalazinone derivatives
BRPI0817537B1 (pt)	2007-10-17	2022-04-05	Kudos Pharmaceuticals Limited	4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona, método para obtê-lo, composição farmacêutica compreendendo o mesmo, bem como usos terapêuticos do dito composto
AR070221A1 (es)	2008-01-23	2010-03-25	Astrazeneca Ab	Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
HUE035295T2 (en)	2008-08-06	2018-05-02	Medivation Technologies Inc	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
UA106878C2 (uk)	2008-10-07	2014-10-27	Астразенека Юк Лімітед	Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
EP2730662A1 (de)	2008-11-12	2014-05-14	Caris Life Sciences Luxembourg Holdings	Verfahren und Systeme zur Verwendung von Exosomen zur Bestimmung von Phänotypen
WO2011007145A1 (en)	2009-07-15	2011-01-20	Astrazeneca Ab	Phthalazinone compound as parp inhibitor
AU2011223789A1 (en)	2010-03-01	2012-09-20	Caris Life Sciences Switzerland Holdings Gmbh	Biomarkers for theranostics
US9469876B2 (en)	2010-04-06	2016-10-18	Caris Life Sciences Switzerland Holdings Gmbh	Circulating biomarkers for metastatic prostate cancer
CN104789664A (zh) *	2015-04-02	2015-07-22	安诺优达基因科技(北京)有限公司	用于乳腺癌易感基因BRCA1和BRCA2的Long-range PCR检测的引物组、方法及试剂盒
JP6786066B2 (ja)	2016-10-07	2020-11-18	富士通株式会社	家系図作成支援プログラム、家系図作成支援方法、及び家系図作成支援装置
CN109897852A (zh) *	2018-07-25	2019-06-18	广州普世利华科技有限公司	基于C2c2的肿瘤相关突变基因的gRNA、检测方法、检测试剂盒
KR20220008869A (ko)	2019-05-14	2022-01-21	누베이션 바이오 인크.	항암 핵 호르몬 수용체-표적화 화합물
WO2021013735A1 (en)	2019-07-19	2021-01-28	Astrazeneca Ab	Parp1 inhibitors
TW202131930A (zh)	2019-11-13	2021-09-01	美商諾維雪碧歐公司	抗癌核荷爾蒙受體標靶化合物
CN113388680B (zh) *	2020-03-14	2023-07-04	复旦大学附属妇产科医院	上皮性卵巢癌靶点ret及其在诊断和治疗中的作用
US11795158B2 (en)	2020-06-25	2023-10-24	Astrazeneca Ab	Chemical compounds
BR112023006337A2 (pt)	2020-10-09	2023-05-09	Astrazeneca Uk Ltd	Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
AU2022246058A1 (en)	2021-03-23	2023-10-05	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
CA3218577A1 (en)	2021-05-03	2022-11-10	Nuvation Bio Inc.	Anti-cancer nuclear hormone receptor-targeting compounds
US20240366584A1 (en)	2021-06-21	2024-11-07	Tesaro, Inc.	Combination treatment of cancer with a parp inhibitor and a lipophilic statin
CN118414173A (zh)	2021-11-18	2024-07-30	阿斯利康(英国)有限公司	抗体-药物缀合物和parp1选择性抑制剂的组合
IL313661A (en)	2021-12-21	2024-08-01	Astrazeneca Ab	Methods of treating brain tumours and neuroblastomas
TW202339805A (zh)	2021-12-28	2023-10-16	英商阿斯特捷利康英國股份有限公司	抗體-藥物結合物及atr抑制劑之組合
WO2023126822A1 (en)	2021-12-28	2023-07-06	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and rasg12c inhibitor
KR20240165390A (ko)	2022-03-16	2024-11-22	아스트라제네카 유케이 리미티드	항-trop2 항체-약물 접합체 요법에 대한 점수산정 방법
IL316019A (en)	2022-04-07	2024-11-01	Astrazeneca Ab	Combined treatment for cancer
AU2023250031A1 (en)	2022-04-07	2024-11-14	Astrazeneca Ab	Combination therapy for treating cancer
AU2023248685A1 (en)	2022-04-07	2024-11-14	Astrazeneca Ab	Combination therapy for treating cancer
CN119317434A (zh)	2022-06-15	2025-01-14	阿斯利康(瑞典)有限公司	用于治疗癌症的组合疗法
WO2024023750A1 (en)	2022-07-28	2024-02-01	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024116094A1 (en)	2022-11-30	2024-06-06	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugates and dnmt inhibitors
WO2024199668A1 (en)	2023-03-31	2024-10-03	Astrazeneca Ab	Dosing regiment of azd5305

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4486530A (en)	1980-08-04	1984-12-04	Hybritech Incorporated	Immunometric assays using monoclonal antibodies
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
CA1188246A (en)	1981-08-31	1985-06-04	Jerry L. Gregory	Immobilized microbe recycle apparatus
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4868105A (en)	1985-12-11	1989-09-19	Chiron Corporation	Solution phase nucleic acid sandwich assay
IE61148B1 (en)	1988-03-10	1994-10-05	Ici Plc	Method of detecting nucleotide sequences
WO1992000311A1 (en) *	1990-06-27	1992-01-09	Princeton University	Probes for detecting mutant p53
IL103059A0 (en)	1991-09-30	1993-02-21	Boehringer Ingelheim Int	Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en)	1991-11-08	1993-10-12	Research Corporation Technologies, Inc.	Safe vector for gene therapy
WO1994000764A1 (en) *	1992-06-26	1994-01-06	THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES	The met proto-oncogene and a method for predicting breast cancer progression
WO1995019369A1 (en) *	1994-01-14	1995-07-20	Vanderbilt University	Method for detection and treatment of breast cancer
AU707348B2 (en) *	1995-01-17	1999-07-08	Vanderbilt University	Method for detection and treatment of breast cancer

1995
- 1995-08-11 DK DK95305605T patent/DK0705903T3/da active
- 1995-08-11 ES ES95305605T patent/ES2158048T5/es not_active Expired - Lifetime
- 1995-08-11 DE DE69521002T patent/DE69521002T3/de not_active Expired - Lifetime
- 1995-08-11 NZ NZ291621A patent/NZ291621A/en not_active IP Right Cessation
- 1995-08-11 AU AU33212/95A patent/AU686004B2/en not_active Expired
- 1995-08-11 MX MX9701075A patent/MX9701075A/es unknown
- 1995-08-11 CN CN95195413.XA patent/CN1172502A/zh active Pending
- 1995-08-11 CA CA002196797A patent/CA2196797C/en not_active Expired - Lifetime
- 1995-08-11 JP JP50750796A patent/JP2002503943A/ja active Pending
- 1995-08-11 AT AT95305605T patent/ATE201445T1/de not_active IP Right Cessation
- 1995-08-11 EP EP95305605A patent/EP0705903B2/de not_active Expired - Lifetime
- 1995-08-11 WO PCT/US1995/010202 patent/WO1996005306A2/en not_active Application Discontinuation
- 1995-08-11 PT PT95305605T patent/PT705903E/pt unknown
1997
- 1997-02-07 FI FI970513A patent/FI970513A/fi unknown
- 1997-02-11 NO NO970624A patent/NO970624L/no not_active Application Discontinuation
2001
- 2001-08-06 GR GR20010401173T patent/GR3036322T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2158048T5 (es)	2009-11-04
CN1172502A (zh)	1998-02-04
EP0705903A1 (de)	1996-04-10
WO1996005306A3 (en)	1996-03-14
NO970624D0 (no)	1997-02-11
AU686004B2 (en)	1998-01-29
EP0705903B1 (de)	2001-05-23
NZ291621A (en)	1998-09-24
CA2196797A1 (en)	1996-02-22
WO1996005306A2 (en)	1996-02-22
PT705903E (pt)	2001-11-30
ES2158048T3 (es)	2001-09-01
DK0705903T3 (da)	2001-08-27
DE69521002T3 (de)	2010-02-25
GR3036322T3 (en)	2001-11-30
CA2196797C (en)	2000-10-10
JP2002503943A (ja)	2002-02-05
AU3321295A (en)	1996-03-07
EP0705903B2 (de)	2009-08-12
ATE201445T1 (de)	2001-06-15
MX9701075A (es)	1998-03-31
FI970513A (fi)	1997-04-07
NO970624L (no)	1997-04-14
FI970513A0 (fi)	1997-02-07
DE69521002T2 (de)	2001-11-15

Publication	Publication Date	Title
DE69521002D1 (de)	2001-06-28	Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
DE69524182D1 (de)	2002-01-10	17Q-Verbundenes Ovarial- und Brustkrebs Empfindlichkeitsgen
NO982785D0 (no)	1998-06-17	Kromosom 13-koblet brystkreftmottagelighetsgen
EP1260520A3 (de)	2002-12-04	Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
AU6473598A (en)	1998-10-20	Method for determining the presence of mutated brca protein
WO1998025125A3 (en)	1999-08-05	Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
MX9701074A (es)	1998-02-28	Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.

Legal Events

Date	Code	Title	Description
2002-05-23	8363	Opposition against the patent
2009-09-24	8328	Change in the person/name/address of the agent	Representative=s name: VOSSIUS & PARTNER, 81675 MUENCHEN
2009-10-22	8366	Restricted maintained after opposition proceedings
2010-01-28	8327	Change in the person/name/address of the patent owner	Owner name: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION, SA, US